Agilent closed the second quarter of fiscal 2026 by doing two things at once that, together, reshape how the market should price the equity. On the operating side, the company delivered 10.0% reported revenue growth, 21.7% GAAP operating margin (a 370 basis point year-over-year expansion), and 26.4% non-GAAP operating margin (130 basis points year-over-year, 180 basis points sequentially) - and then raised full-year guidance for the second consecutive quarter. On the capital side, twenty-nine days after quarter-end, Agilent issued $600 million of 4.900% senior notes due 2032, taking advantage of an investment-grade tape that is open to long-duration, science-rated credit.
We see this as the moment the equity story transitions from a "rebuild after the FY2024 pharma capex cliff" narrative into a structurally higher-margin compounder, funded by a balance sheet that was already net-debt-light and now gets a refinancing window with the long end at 4.9%. The market at $148.53 is paying roughly 24.6x the raised midpoint of fiscal 2026 non-GAAP EPS guidance ($6.05) and 29.9x our $4.96 estimate of trailing twelve-month GAAP EPS - a multiple that is full but, in our view, defensible if the Ignite cost program and the Biocare close land on schedule.
The load-bearing question for the next 90 days is whether the second half of fiscal 2026 can deliver the "core" 4.5% to 6.0% full-year revenue growth that management just committed to with the raise. The falsifiable clock is the third-quarter earnings print in late August/early September 2026, when Agilent reports against a Q3 FY2026 guide of $1.83 billion to $1.85 billion in revenue and $1.48 to $1.50 in non-GAAP EPS. Miss that range by 100 basis points on revenue, and the multiple compresses; deliver it, and the FY2027 setup - with Biocare consolidated, Ignite cost-out fully annualized, and the new senior notes only one quarter into the run-rate - becomes the next leg of the story.